Sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor that displays selectivity over other NHE isoforms (Ki
values are 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3 respectively). Inhibits NHE1 dependent 22
uptake in vitro
= 14 nM) and provides cardioprotection from myocardial ischemic injury in vivo
= 0.25 nM). Also inhibits MMP2/9 activity and invasion in breast cancer cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc
A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo.
Knight et al.
Zoniporide: a potent and highly selective inhibitor of human Na+/H+ exchanger-1.
Marala et al.
Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform-1, in an experimental model of cardiopulmonary bypass.
Clements-Jewery et al.
The citations listed below are publications that use Tocris products. Selected citations for Zoniporide dihydrochloride include:
Showing Results 1 - 1 of 1